# US 2025/0082628 A1 · INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082628 A1
- Document ID: US20250082628A1
- Status: Published application
- Kind: A1
- Application number: 18/611,335
- Filed: 2024-03-20
- Published: 2025-03-13
- Earliest claimed: 2018-05-16
- Assignees: FORMA Therapeutics, Inc.
- Applicants: FORMA Therapeutics, Inc.
- Inventors: Patrick F. Kelly; Susan Ashwell; Blythe Thomson; Alan Collis; Jeff Davis; Duncan Walker; Wei Lu
- Web page: https://patentgrep.com/patent/US20250082628A1

## CPC

- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

## Claims

### Claim 1

A method of treating a patient diagnosed with a solid tumor characterized by an IDH1 mutation, the method comprising orally administering to the patient in need thereof a pharmaceutical composition comprising a total of 150 mg of olutasidenib twice per day (BID).

### Claim 2 (depends on 1)

The method of claim 1, wherein the olutasidenib is administered as a single agent.

### Claim 3 (depends on 1)

The method of claim 1, wherein the solid tumor is selected from glioma, hepatobiliary carcinoma, chondrosarcoma, and intrahepatic cholangiocarcinoma.

### Claim 4 (depends on 1)

The method of claim 1, wherein the olutasidenib is administered to the patient in need thereof in a tablet or capsule oral unit dosage form on consecutive days throughout a course of treatment.

### Claim 5 (depends on 4)

The method of claim 4, wherein the course of treatment is at least 15 consecutive days.

### Claim 6 (depends on 4)

The method of claim 4, wherein the course of treatment is at least 6 months.

### Claim 7 (depends on 1)

The method of claim 1, wherein the solid tumor is characterized by an R132 IDH1 mutation.

### Claim 8

A method of treating a patient diagnosed with a glioma characterized by an IDH1 mutation, the method comprising orally administering to the patient in need thereof a pharmaceutical composition comprising a total of 150 mg of olutasidenib twice per day (BID).

### Claim 9 (depends on 8)

The method of claim 8, wherein the olutasidenib is administered as a single agent.

### Claim 10 (depends on 8)

The method of claim 8, wherein the glioma is characterized by an R132 IDH1 mutation.

### Claim 11 (depends on 10)

The method of claim 10, wherein the R132 IDH1 mutation is selected from R132C, R132H, R132G, R132S, and R132L.

### Claim 12 (depends on 10)

The method of claim 10, wherein the glioma is further characterized by at least one mutation selected from TP53, GFAP, TERT, MGMT, 1p19q, OLIG2, ATRX, PI3K3CA, CDKN2B, CDKN2A, PTEN, NogoA, and DNMT3A.

### Claim 13 (depends on 10)

The method of claim 10, wherein the glioma is further characterized by at least one mutation selected from DNMT3A, TP53, ATM, and NRAS.

### Claim 14 (depends on 8)

The method of claim 8, wherein the glioma is relapsed/refractory mIDH1 glioma.

### Claim 15 (depends on 8)

The method of claim 8, wherein the patient has previously received temozolomide to treat a mIDH1 glioma prior to administration of the olutasidenib to the patient.

### Claim 16 (depends on 8)

The method of claim 8, wherein the olutasidenib is administered to the patient in need thereof in a tablet or capsule oral unit dosage form on consecutive days throughout a course of treatment of at least 15 consecutive days.

### Claim 17

A method of treating a patient diagnosed with a cancer characterized by (i) an R132 IDH1 mutation and (ii) a concurrent mutation, the method comprising orally administering to the patient in need thereof a pharmaceutical composition comprising a total of 150 mg of olutasidenib twice per day (BID).

### Claim 18 (depends on 17)

The method of claim 17, wherein the concurrent mutation is selected from CEBPA, DNMT3A, NPM1, SRSF2, NRAS, RUNX1, ASXL1, FLT3, STAG2, IDH2, TET2, SMC1A, SF3B1, U2AF1, PHF6, JAK2, MPL, NF1, ASXL2, BCOR, EED, WT1, CBL, CSF3R, ETNK1, PTPN11, ATM, TP53, EZH2, SETBP1, GATA2, CBP, CUX1, GFAP, TERT, MGMT, 1p19q, OLIG2, ATRX, PI3K3CA, CDKN2B, CDKN2A, PTEN, and NogoA.

### Claim 19 (depends on 17)

The method of claim 17, wherein the R132 IDH mutation is selected from R132G, R132S, and R132L.

### Claim 20 (depends on 17)

The method of claim 17, wherein the olutasidenib is administered to the patient in need thereof in a tablet or capsule oral unit dosage form on consecutive days throughout a course of treatment of at least 15 consecutive days.
